Vivo Bio Tech secures pre-clinical testing contract valued at Rs.10.75 Cr
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
The facility will be positioned as a Centre of Excellence for tertiary care services
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Inclacumab was generally well tolerated in THRIVE-131
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Subscribe To Our Newsletter & Stay Updated